Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of RAE 1 gene or protein as biomarker for diagnosing myocardial infarction

A myocardial infarction and gene technology, which is applied in the application field of biomarkers, can solve the problem of unclear expression of related genes, and achieve the effects of early diagnosis, reduction of mortality, and timely gene diagnosis.

Active Publication Date: 2018-10-09
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A variety of physiological processes accompany the occurrence of myocardial infarction, such as inflammation, abnormal calcium uptake, cell cycle abnormalities, peptide secretion, oxidative stress, apoptosis, etc., and the precise timing of these processes and the occurrence of myocardial ischemia are currently unknown. When some related genes are expressed is not clear and needs to be further explored

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of RAE 1 gene or protein as biomarker for diagnosing myocardial infarction
  • Application of RAE 1 gene or protein as biomarker for diagnosing myocardial infarction
  • Application of RAE 1 gene or protein as biomarker for diagnosing myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Screening of genes differentially expressed in patients with myocardial infarction and normal people

[0035] 1. Research object

[0036] Select 6 hospitalized patients with myocardial infarction treated in the hospital as research objects, including 3 males and 3 females, with an average age of 56.00±8.75; 7 healthy people in the control group; each of the above-mentioned patients and healthy people who were invited to participate in the study All signed the informed consent.

[0037] 2. Sample collection and storage

[0038] On the day of admission, 8 mL of fresh sterile arterial blood was collected into EDTA anticoagulated purple tubes before coronary angiography. If it is not used immediately, the sample can be stored in a refrigerator at 4°C for 2 hours.

[0039] 3. Separation of PBMCs by Ficoll method

[0040] The following steps are all completed in the ultra-clean bench:

[0041] (1) Dilute the blood sample with equal volume of normal saline, add ...

Embodiment 2

[0063] Embodiment 2QPCR experiment verifies the genes differentially expressed in patients with myocardial infarction and normal people

[0064] 1. Research object:

[0065] The screening criteria were the same as in Example 1, 35 patients with myocardial infarction and 35 normal subjects.

[0066] 2. Extraction of total RNA in blood

[0067] Step is with embodiment 1.

[0068] 3. RT-PCR

[0069] (1)RT

[0070] RT reaction system (20μl):

[0071]

[0072]

[0073] RT reaction procedure:

[0074] 42°C 15min

[0075] 85℃ 5s

[0076] 4℃ ---

[0077] (2) qPCR

[0078] PCR reaction system (20μl):

[0079]

[0080] PCR reaction program:

[0081] Amplification procedure:

[0082] Stage 1 95°C 10min

[0083] Stage 2 95°C 10s

[0084] 56°C 10s

[0085] Repeat for 35 cycles

[0086] Three replicate wells were set for each sample, and the internal reference was GAPDH.

[0087] (3) Primers

[0088] The primer sequences of RAE1 gene and GAPDH gene are as follows: ...

Embodiment 3

[0102] Example 3 Western blot experiment to verify the expression products of differentially expressed genes in patients with myocardial infarction and normal people

[0103] 1. Research object: same as embodiment 2.

[0104] 2. Mononuclear cell isolation

[0105] Take 10ml of venous blood from patients with myocardial infarction and normal people, inject it into a sterile vial containing heparin, and shake it gently immediately after capping. Add an equal volume of HBSS (NaCl 8.0g, NaCl 2 HPO 4 0.132g, KH 2 PO 4 0.06g, KCl0.4g, phenol red 1ml, NaHCO 3 0.35g, D-glucose 1.0g, dissolved in 1000ml double distilled water), to reduce the aggregation of red blood cells. Draw 8ml of lymphocyte stratification solution into a 50ml centrifuge tube, slowly add the diluted blood along the tube wall, keep the interface clear, do not mix the two, centrifuge at 20°C 2000r / min for 30min, carefully absorb the stratification solution and plasma transfer The turbid off-white layer, tha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of RAE 1 gene or protein as a biomarker for diagnosing myocardial infarction. The content of an RAE1 gene in the blood of a myocardial infarction patient has an obvious difference from normal people, and the myocardial infarction patient and normal crowds can be distinguished according to the difference. The invention also discloses a diagnosis product for the myocardial infarction, and the diagnosis product can be used for realizing a myocardial infarction diagnosis purpose through the detection of the RAE1 gene in the blood.

Description

technical field [0001] The invention belongs to the field of molecular diagnosis and relates to the application of RAE1 gene or protein as a biomarker for diagnosing myocardial infarction. Background technique [0002] Myocardial infarction is a global public health problem that seriously threatens public health (J.Ross, Jr., A50-year research journey. From laboratory to clinic, Circulation journal: official journal of the Japanese Circulation Society, 73(2009 ) 3-12; D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T. B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, N. Haase , S. Hailpern, M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. McDermott, J. Meigs, D. Mozaffarian, G. Nichol, C . O'Donnell, V. Roger, W. Rosamond, R. Sacco, P Sorlie, R. Stafford, J. Steinberger, T. Thom, S. Wasserthiel-Smoller, N. Wong, J. Wylie-Rosett, Y. Hong, C. American Heart Association Statistics, S.). Several methodologies can be effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883G01N33/68
Inventor 李曙光靳传娣
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com